A5016015982- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Renal Transplantation Outcomes and Treatments
- Neutropenia and Cancer Infections
- Pharmacological Effects and Toxicity Studies
- Acute Myeloid Leukemia Research
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Nausea and vomiting management
- Cytomegalovirus and herpesvirus research
- Wound Healing and Treatments
- Spectroscopy Techniques in Biomedical and Chemical Research
- Antifungal resistance and susceptibility
- Polyomavirus and related diseases
- Palliative Care and End-of-Life Issues
- Chronic Myeloid Leukemia Treatments
- Pluripotent Stem Cells Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Electrolyte and hormonal disorders
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
University of North Carolina Health Care
2018-2025
University of North Carolina at Chapel Hill
2018-2023
University of North Carolina Hospitals
2020-2021
Abstract Background Tixagevimab-cilgavimab (tixa-cil), was approved for emergency use authorization by the FDA in December of 2021 pre-exposure prophylaxis COVID-19 virus immunocompromised populations due to concerns about vaccine efficacy. Data regarding real world efficacy tixa-cil preventing SARS-CoV-2 infection patients is limited.Table 1Patient Demographics Methods We conducted a retrospective analysis all who had received hematopoietic cell transplantation (HCT) or chimeric antigen...
Tacrolimus exhibits high inter-patient pharmacokinetics (PK) variability, as well a narrow therapeutic index, and therefore requires drug monitoring. Germline mutations in cytochrome P450 isoforms 4 5 genes (CYP3A4/5) the ATP-binding cassette B1 gene (ABCB1) may contribute to interindividual tacrolimus PK which impact clinical outcomes among allogeneic hematopoietic stem cell transplantation (HSCT) patients. In this study, 252 adult patients who received for acute graft versus host disease...
A paucity of data currently exists regarding drug–drug interaction (DDI) with tacrolimus and isavuconazole coadministration. Current literature provides conflicting recommendations on whether an empiric dose reduction is necessary when coadministered isavuconazole. 47-year-old African American female acute lymphoblastic leukemia underwent allogenic stem cell transplant (alloSCT) was subsequently placed routine posttransplant therapy including for immunosuppression posaconazole antifungal...
Targeted busulfan dosing helps limit chemotherapy-related toxicity and optimize disease outcomes in hematopoietic stem cell transplantation (HCT). The objective of this study was to evaluate exposure from a pharmacokinetic (PK)-guided strategy using test dose. This retrospective evaluation included adult patients who underwent HCT at our institution with busulfan-based myeloablative (>9 mg/kg) conditioning between January 2014 October 2015. A weight-based dose 0.8 mg/kg used PK assessments...
Abstract Tacrolimus is a calcineurin inhibitor used to prevent acute graft versus host disease in adult patients receiving allogeneic hematopoietic stem cell transplantation (HCT). Previous population pharmacokinetic (PK) models have been developed solid organ transplant, yet none exists for HCT. The primary objectives of this study were (1) use previously published PK model who underwent kidney transplant and apply it HCT; (2) evaluate model‐predicted tacrolimus steady‐state trough...
Abstract Busulfan is an alkylating agent used as part of conditioning chemotherapy regimens prior to allogeneic hematopoietic cell transplant (allo‐HCT). Pharmacokinetic (PK)‐guided test‐dose strategies have been shown improve the number patients achieving busulfan exposure goals and clinical outcomes. However, current practices require extensive PK sampling. In this study, data were retrospectively collected from drug monitoring records adult allo‐HCT recipients who received once‐daily...
To develop the first population pharmacokinetic (PopPK) model for oral tacrolimus in adult allogeneic hematopoietic cell transplant (allo-HCT) recipients, we conducted a prospective clinical pharmacology study among real-world patients (NCT04645667). This commentary describes challenges associated with planning and executing during global pandemic, provides insights on how to effectively communicate, remain adaptable institutional changes, improve consent rate, accommodate new workflows...
Plerixafor is a hematopoietic stem cell mobilizing agent used in combination with granulocyte-colony stimulating factor to improve collection for autologous transplantation. Despite recommendation administration 11 h prior apheresis per package labeling, logistical challenges lead many institutions administer plerixafor at an extended interval. The purpose of this study was determine if effectively and efficiently mobilizes CD34+ cells when given interval apheresis. This retrospective...
Abstract Purpose: Chemotherapy-induced nausea and vomiting (CINV) remains a significant barrier to quality of life. Hematopoietic cell transplant (HCT) recipients often receive highly emetogenic chemotherapy (HEC) that increases incidence CINV. Guideline recommendations include olanzapine plus corticosteroid, serotonin antagonist, neurokinin-1 antagonist for CINV prophylaxis in patients receiving HEC. However, olanzapine’s role prevention during HCT has not been evaluated prospectively....